Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 3, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions
Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Interventions
DRUG

Linperlisib

"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."

Trial Locations (3)

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

RECRUITING

Zhoukou Central Hospital, Zhoukou

RECRUITING

Regenerative Medicine Center, Tianjin

All Listed Sponsors
collaborator

YL-Pharma

UNKNOWN

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER